Association of the C677T MTHFR polymorphism with homocysteine, Ox-LDL levels, and thiolactonase activities in the severity of coronary syndrome

Clinical and Applied Thrombosis/Hemostasis

Volumn 16, Issue 5, 2010, Pages 515-521

  Koubaa, Nadia ^a   Nakbi, Amel ^a   Hammami, Sonia ^b   Mehri, Sounira ^a   Attia, Nabil ^a   Ben Farhat, Mohamed ^b   Hammami, Mohamed ^a  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b FATTOUMA BOURGUIBA UNIVERSITY HOSPITAL   (Tunisia)

Author keywords

Coronary artery disease; Homocysteine; Methylenetetrahydrofolate reductase; Oxidized LDL; Thiolactonase

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); C REACTIVE PROTEIN; ESTERASE; HIGH SENSIBILITY C REACTIVE PROTEIN; HOMOCYSTEINE; HOMOCYSTEINE THIOLACTONASE; OXIDIZED LOW DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE SEVERITY; DNA POLYMORPHISM; ENZYME ACTIVITY; FEMALE; GENE MUTATION; GENOTYPE; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

AGED; C-REACTIVE PROTEIN; CARBOXYLIC ESTER HYDROLASES; COHORT STUDIES; CORONARY ARTERY DISEASE; FEMALE; GENOTYPE; HOMOCYSTEINE; HUMANS; LIPOPROTEINS, LDL; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 77955878440     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029610369798     Document Type: Article

References (36)

1. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA. 1995 ; 274 (13). 1049-1057.
2. Clarke R., Daly L., Robinson K., et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991 ; 324 (17). 1149-1155.
3. Kang S-S., Zhou J., Wong PWK, Kowalisyn J., Strokosch G. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet. 1988 ; 43 (4). 414-421.
4. Frosst P., Blom HJ, Milos R., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995 ; 10 (1). 111-113.
5. Engbersen AMT, Franken DG, Boers GHJ, Stevens EMB, Trijbels JMF, Blom HJ Thermolabile 5,10-methylenetetrahydro folate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet. 1995 ; 56 (1). 142-150.
6. Kang S-S., Passen EL, Ruggie N., Wong PWK, Sora H. Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease. Circulation. 1993 ; 88 (4 pt 1). 1463-1469.
7. Jakubowski H. Biochemical basis of homocysteine toxicity in humans. Mol Cell Life Sci. 2004 ; 61 (4). 470-487.
8. Jakubowski H. Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. FASEB J. 1999 ; 13 (15). 2277-2283.
9. Nishi K., Itabe H., Uno M., et al. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol. 2002 ; 22 (10). 1649-1654.
10. Ehara S., Ueda M., Naruko T., et al. Elevated levels of low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation. 2001 ; 103 (15). 1955-1960.
11. Koubaa N., Hammami S., Nakbi A., et al. Relationship between thiolactonase activity and hyperhomocysteinemia according to MTHFR gene polymorphism in Tunisian Behçet's disease patients. Clin Chem Lab Med. 2008 ; 46 (2). 187-192.
12. Smaoui M., Hammami S., Chaaba R., et al. Lipids and lipoprotein (a) concentration in Tunisian type 2 diabetic patients relationship to glycaemic control and coronary heart disease. J Diabetes Complication. 2004 ; 18: 258-263.
13. Koubaa N., Nakbi A., Smaoui M., et al. Hyperhomocysteinemia and elevated ox-LDL in Tunisian type 2 diabetic patients: role of genetic and dietary factors. Clin Biochem. 2007 ; 40 (13-14). 1007-1014.
14. Meleady R., Ueland PM, Blom H., et al. Thermolabile methylenetetrahydrofolate reductase, homocysteine, and cardiovascular disease risk: the European Concerted Action Project. Am J Clin Nutr. 2003 ; 77 (1). 63-70.
15. Ilhan N., Kucuksu M., Kaman D., Ilhan N., Ozbay Y. The 677 C/T MTHFR polymorphism is associated with essential hypertension, coronary artery disease, and higher homocysteine levels. Arch Med Res. 2008 ; 39 (5). 125-130.
16. Outinen PA, Sood SK, Liaw PC, et al. Characterization of the stress-inducing effects of homocysteine. Biochem J. 1998 ; 332 (pt 1). 213-221.
17. Upchurch GR Jr, Welch GN, Fabian AJ, et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem. 1997 ; 272 (27). 17012-17017.
18. Refsum H., Ueland PM Recent data are not in conflict with homocysteine as a cardiovascular risk factor. Curr Opin Lipidol. 1998 ; 9 (6). 533-539.
19. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol. 1995 ; 15 (5). 551-561.
20. Hurt-Camejo E., Olsson U., Wiklund O., Bondjers G., Camejo G. Cellular consequences of the association of apoB lipoproteins with proteoglycans. Potential contribution to atherogenesis. Arterioscler Thromb Vasc Biol. 1997 ; 17 (6). 1011-1017.
21. Sniderman AD, Pedersen T., Kjekshus J. Putting low-density lipoproteins at center stage in atherogenesis. Am J Cardiol. 1997 ; 79 (1). 64-67.
22. Boers GHJ, Smals AGH, Trijbels JMF, et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med. 1985 ; 313 (12). 709-715.
23. Arnesen E., Refsum H., Bonaa KH, Ueland PM, Forde OH, Nordrehaug JE Serum total homocysteine and coronary heart disease. Int J Epidemiol. 1995 ; 24 (4). 704-709.
24. Kang S. -S, Wong PWK, Cook HY, Norusis M., Messer JV Protein-bound homocyst(e)ine: a possible risk factor for coronary artery disease. J Clin Invest. 1986 ; 77 (5). 1482-1486.
25. Nygård O., Vollset SE, Refsum H., et al. Total plasma homocysteine and cardiovascular risk profile: the Hordaland Homocysteine Study. JAMA. 1995 ; 274 (19). 1526-1533.
26. Selhub J., Jacques PF, Bostom A., et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med. 1995 ; 332 (5). 286-291.
27. Almawi WY, Ameen G., Tamim H., Finan RR, Irani-Hakime N. Factor V G1691A, prothrombin G20210A, and methylenetetrahydrofolate reductase [MTHFR] C677T gene polymorphism in angiographically documented coronary artery disease. J Thromb Thrombolysis. 2004 ; 17 (3). 199-205.
28. Morita H., Taguchi J., Kurihara H., et al. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation. 1997 ; 95 (8). 2032-2036.
29. Jee SH, Beaty TH, Suh I., Yoon Y., Appel LJ The methylenetetrahydrofolate reductase gene is associated with increased cardiovascular risk in Japan, but not in other populations. Atherosclerosis. 2000 ; 153 (1). 161-168.
30. Wilcken DE, Wang XL, Sim AS, McCredie RM Distribution in healthy and coronary populations of the methylenetetrahydrofolate reductase (MTHFR) C677T mutation. Arterioscler Thromb Vasc Biol. 1996 ; 16 (7). 878-882.
31. Ma J., Stampfer MJ, Henneken CH, et al. Methylenetetrahydrofolate polymorphism, plasma folate, homocysteine, and risk of myocordias infarction in US physicians. Circulation. 1996 ; 94 (10). 2410-2416.
32. Rothenbacher D., Fischer HG, Hoffmeister A., et al. Homocysteine and methylenetetrahydrofolate reductase genotype: association with risk of coronary heart disease and relation to inflammatory, hemostatic, and lipid parameters. Atherosclerosis. 2002 ; 162 (1). 193-200.
33. Zuntar I., Topic E., Vukosavic D., et al. Croatian population data for the C677T polymorphism in methylenetetrahydrofolate reductase: frequencies in healthy and atherosclerotic study groups. Clin Chim Acta. 2003 ; 335 (1-2). 95-100.
34. Kalina A., Czeizel AE The methylenetetrahydrofolate reductase gene polymorphism (C677T) is associated with increased cardiovascular mortality in Hungary. Int J Cardiol. 2004 ; 97 (2). 333-334.
35. Goyette P., Frosst P., Rosenblatt DS, Rozen R. Seven novel mutations in the methylenetetrahydrofolate reductase gene and genotype:phenotype correlation in severe méthylénetétrahydrofolate reductase deficiency. Am J Hum Genet. 1995 ; 56 (5). 1052-1059.
36. Harker LA, Harlan JM, Ross R. Effect of sulfinpyrazone on homocysteine-induced endothelial injury and arteriosclerosis in baboons. Circ Res. 1983 ; 53 (6). 731-739.